Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.150616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Yiqing Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cisplatin, Drug Resistance, Neoplasm, Mitochondria. Die Arbeit nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cisplatin (DDP) resistance in advanced stages of ovarian cancer significantly reduces survival rates. Mitochondria may serve as a potential therapeutic target for ovarian cancer. Pal-pHK-pKV is a mitochondrial targeting peptide synthesized by supramolecular assembly. Our study aims to investigate whether Pal-pHK-pKV serves as a useful strategy to reverse DDP resistance in ovarian cancer. Subcutaneous tumor implantation of the DDP-resistant ovarian cancer cell line A2780CP was conducted in nude mice, and drugs were administered intraperitoneally to compare the inhibitory effects of Pal-pHK-pKV and DDP on A2780CP cells in vivo. Combination index values were calculated for various concentrations of DDP and Pal-pHK-pKV to determine the optimal combination concentration. Mitochondrial membrane potential, cytochrome C distribution and immunofluorescence were also measured. Our studies demonstrated that Pal-pHK-pKV treatment reduced the proliferation, invasion and metastasis of ovarian cancer cells and impaired mitochondrial function. Furthermore, the combination of Pal-pHK-pKV and DDP exhibited a synergistic effect. Mechanistically, Pal-pHK-pKV can impair mitochondrial function, reduce mitochondrial membrane potential and release ROS. On the other hand, Pal-pHK-pKV can affect ERK pathway activation and inhibit tumor development. In conclusion, the mitochondria-specific amphiphilic peptide Pal-pHK-pKV provides a novel approach for treating ovarian cancer and may potentially overcome DDP drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, China. Electronic address: aihuazou@shnu.edu.cn.
- Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China. Electronic address: yangling@fudan.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, Y., Zhang, J., Zeng, H., Gui, A., Yan, Y., Zou, A., & Yang, L. (2024). Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150616
Vancouver
Yuan Y, Zhang J, Zeng H, Gui A, Yan Y, Zou A, et al. Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150616
BibTeX
@article{Yuan2024,
author = {Yuan, Yiqing and Zhang, Junyi and Zeng, Hongya and Gui, Ailin and Yan, Yichen and Zou, Aihua and Yang, Ling},
title = {Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.150616}
}
EUVIMED